ABT•Abbott said its investigational SonicForce coronary device met the TECTONIC trial’s primary safety and effectiveness endpoints, with low treatment failure and high procedural success.
Abbott’s investigational SonicForce coronary device met the TECTONIC trial’s primary safety and effectiveness endpoints, showing low treatment failure and high procedural success. Results were presented at the Transcatheter Cardiovascular Therapeutics conference in San Diego and published in JACC: Cardiovascular Interventions. The device uses acoustic pressure waves to crack coronary calcium before stenting.
